Dawnrays Pharmaceutical (Holdings) Limited (“Dawnrays Pharma” or the “Group”, The Stock Exchange of Hong Kong Stock Code: 2348) announced that Levamlodipine Besylate Tablets ( 苯磺酸左旋氨氯地平片)(Trade name: 安美平^® (Anmeiping)), a cardiovascular therapeutic drug and Cefprozil Tablets (頭孢丙烯片) (Trade name: 司力可^® (Silike)), an oral cephalosporin antibiotic, two new generic drugs of Suzhou Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the Group, have been granted production approvals from the State Food and Drug Administration (SFDA), the approval numbers are Guo Yao Zhun Zi ( 國藥准字) H20103814 and Guo Yao Zhun Zi (國藥准字) H20103792 respectively, and anticipates their production and sales will start in the near term.

In the past 8 years, Dawnrays Pharma has been eager to make enthusiastic progress in the cardiovascular field. The key product 安內真^® (Anneizhen) and related series of products have a rapid growth in sales in recent years. At the same time, with the implementation of the “Chinese Hypertension Intervention Efficacy Study” (“CHIEF” study) under the National Science and Technology Pillar Program during the “Eleventh Five-year Plan” period ( 國家「十一‧五」科技支撐計劃「高血壓綜合防治研究」) is bringing into practice, the Group has gradually formed a stronger brand dominance. Thus, turned into one of the significant sources of profit for the Group. The soon to be marketed Levamlodipine Besylate Tablets (苯磺酸左旋氨氯地平片) has been included in the National Essential Drug List  (國家基本藥物目錄) in various provinces and cities in China. The market size is over

RMB one billion yuan as there is a wide range of patients population. This product and the original series of 安內真^® (Anneizhen) can complement each other and so it would complete and enrich the cardiovascular product line of the Group. And it is expected to further expand the Group’s sales volume of cardiovascular therapeutic drugs.

Cefprozil Tablets ( 頭孢丙烯片) is a new type of the second generation cephalosporin for oral use. It has been included in the National Medical Insurance Catalogue (國家醫保目錄). Affected by the continuity of reinforcement to the Antibiotics Use Standard in China, the new type of second generation cephalosporin for oral use has larger market demand. To inherit Dawnrays Pharma’s powerful production capacity in cephalosporin antibiotics territory, the prudent marketing strategy and the extensive coverage distribution network, the Group anticipates this product will accomplish a speedy market penetration after launch, effectively improve the Group’s market share in the field of cephalosporin antibiotic drugs for oral use.